Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03655678
Other study ID # CTX001-111
Secondary ID
Status Active, not recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date September 14, 2018
Est. completion date August 2024

Study information

Verified date November 2023
Source Vertex Pharmaceuticals Incorporated
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in subjects with transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 45
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 12 Years to 35 Years
Eligibility Key Inclusion Criteria: - Diagnosis of transfusion-dependent ß-thalassemia (TDT) as defined by: 1. Documented homozygous ß-thalassemia or compound heterozygous ß-thalassemia including ß-thalassemia/hemoglobin E (HbE). Subjects can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning. 2. History of at least 100 mL/kg/year or =10 units/year of packed RBC transfusions in the prior 2 years before signing the consent or the last rescreening for patients going through re-screening. - Eligible for autologous stem cell transplant as per investigator's judgment. Key Exclusion Criteria: - A willing and healthy 10/10 Human Leukocyte Antigen (HLA)-matched related donor is available per investigator's judgement. - Prior allo-HSCT. - Subjects with associated a-thalassemia and >1 alpha deletion or alpha multiplications. - Subjects with sickle cell beta thalassemia variant. - Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator. - White blood cell (WBC) count <3 × 10^9/L or platelet count <50 × 10^9/L not related to hypersplenism. Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design


Intervention

Biological:
CTX001
Administered by IV infusion following myeloablative conditioning with busulfan

Locations

Country Name City State
Canada The Hospital for Sick Children Toronto
Canada British Columbia Children's Hospital Vancouver
Germany Universitätsklinikum Düsseldorf Hospital Duesseldorf Düsseldorf
Germany Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine Regensburg
Germany University Hospital Tübingen Tuebingen
Italy Ospedale Pediatrico Bambino Gesù, IRCCS Rome
United Kingdom Imperial College Healthcare NHS Trust, Hammersmith Hospital London
United Kingdom University College London Hospitals NHS Foundation Trust London
United States Ann & Robert Lurie Children's Hospital of Chicago Chicago Illinois
United States The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers Nashville Tennessee
United States Columbia University Medical Center New York New York
United States Columbia University Medical Center (21+ years) New York New York
United States Lucile Packard Children's Hospital Palo Alto California
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Vertex Pharmaceuticals Incorporated CRISPR Therapeutics

Countries where clinical trial is conducted

United States,  Canada,  Germany,  Italy,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects achieving transfusion independence for at least 12 consecutive months (TI12) From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion]
Primary Proportion of subjects with engraftment (first day of 3 consecutive measurements of absolute neutrophil count [ANC] =500/µL on three different days) Within 42 days after CTX001 infusion
Primary Time to neutrophil and platelet engraftment Days post-infusion to engraftment
Primary Frequency and severity of collected adverse events (AEs) Signing of informed consent through Month 24 visit
Primary Incidence of transplant-related mortality (TRM) Baseline (pre-transfusion) to 100 days and 1 year post-CTX001 infusion
Primary All-cause mortality Signing of informed consent through Month 24 visit
Secondary Proportion of subjects achieving transfusion independence for at least 6 consecutive months (TI6) From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion
Secondary Proportion of subjects achieving at least 95 percent (%), 90%, 85%, 75%, and 50% reduction from baseline in annualized transfusions 60 days after CTX001 infusion From Day 60 up to 24 months post-CTX001 infusion
Secondary Relative change from baseline in transfusions 60 days after CTX001 infusion From Day 60 up to 24 months post-CTX001 infusion
Secondary Duration of transfusion free in subjects who have achieved TI12 From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion
Secondary Proportion of alleles with intended genetic modification in peripheral blood leukocytes over time Day 1 CTX001 infusion through Month 24 visit
Secondary Proportion of alleles with intended genetic modification present in CD34+ cells of bone marrow over time Day 1 CTX001 infusion through Month 24 visit
Secondary Change in fetal hemoglobin concentration over time Baseline (pre-transfusion) through Month 24 visit
Secondary Change in total hemoglobin concentration over time Baseline (pre-transfusion) through Month 24 visit
Secondary Change in health-related quality of life (HRQoL) from baseline over time using EuroQol Questionnaire (5 dimensions - 5 levels of severity - EQ-5D-5L) The EQ-5D-5L Questionnaire consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The EQ-5D comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and 5 levels: no problems to extreme problems. The subject marks the most appropriate statement in each dimension, resulting in a 1-digit number for that dimension. The digits can be combined in a 5-digit number describing the subject's health state. The EQ VAS records the subject's self-rated health on a 100-point VAS, endpoints labelled "the best health you can imagine" and "the worst health you can imagine." Screening visit through Month 24 visit
Secondary Change in health-related quality of life (HRQoL) from baseline over time using the Functional assessment of cancer therapy-bone marrow transplant questionnaire (FACT-BMT) The FACT-BMT Questionnaire includes physical, social, family, emotional, and functional well-being, and treatment specific concerns of bone marrow transplantation. Each statement has a 5-point Likert-type response scale ranging from 0=not at all to 4=very much. The subject marks one number per line as it applies to the past 7 days. Questionnaires are scored; the higher the score, the better the QOL. Screening visit through Month 24 visit
Secondary Change in patient reported outcome (PRO) over time assessed using EQ-5D-Youth (EQ-5D-Y) Screening visit through Month 24 visit
Secondary Change in PRO over time assessed using pediatric quality of life inventory (PedsQL) Screening visit through Month 24 visit
Secondary Changes in liver iron concentration (LIC) and cardiac iron content (CIC) and ferritin parameters of iron overload Screening visit through Month 24 visit
Secondary Proportion of subjects receiving iron chelation therapy 1 month post-CTX001 infusion through Month 24 visit
See also
  Status Clinical Trial Phase
Recruiting NCT04094844 - Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation N/A
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Recruiting NCT03918343 - Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation N/A
Completed NCT01445561 - Ultra Low Dose Interleukin-2 in Healthy Volunteers Phase 1
Recruiting NCT06148610 - Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
Completed NCT04168983 - Impact of Sophrology on the Pain Felt During a Bone Marrow Aspiration and Biopsy N/A
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Completed NCT01108159 - Integrated Whole-Genome Analysis of Hematologic Disorders
Completed NCT00800839 - Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide Phase 2
Completed NCT00213239 - A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children Phase 1/Phase 2
Terminated NCT00208949 - A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF Phase 2
Terminated NCT00176826 - T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Phase 2/Phase 3
Completed NCT00208962 - Allogeneic Cell Therapy for Adults With Hematologic Malignancies Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Completed NCT00000587 - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection Phase 2
Recruiting NCT05487794 - Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men With Erythrocytosis N/A
Completed NCT03611257 - Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases N/A
Completed NCT02827149 - High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT
Completed NCT04584528 - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease N/A